Status:
COMPLETED
Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
Lead Sponsor:
KU Leuven
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS pati...
Eligibility Criteria
Inclusion
- Irritable Bowel Syndrome (ROME III criteria)
- age 18-65 years
Exclusion
- medication: antidepressants or H1-receptor antagonists
- pregnancy, breast feeding
- co-morbidity: severe kidney- and/or liver disease
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01144832
Start Date
October 1 2009
End Date
May 1 2012
Last Update
January 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospitals Leuven
Leuven, Vlaams-Brabant, Belgium, 3000